Predictors of competing mortality in advanced head and neck cancer

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 15-20

  Mell, Loren K ^a   Dignam, James J ^a   Salama, Joseph K ^a   Cohen, Ezra E W ^a   Polite, Blase N ^a   Dandekar, Virag ^a   Bhate, Amit D ^a   Witt, Mary Ellyn ^a   Haraf, Daniel J ^a   Mittal, Bharat B ^a   Vokes, Everett E ^a   Weichselbaum, Ralph R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEFITINIB; HYDROXYUREA; PACLITAXEL;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMORBIDITY; CONTINUOUS INFUSION; FEMALE; GENDER; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HEAD AND NECK TUMOR; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED;

EID: 73949129781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.9288     Document Type: Article

References (30)

1. National Cancer Institute: A Snap Shot of Head and Neck Cancers. Bethesda, MD, National Cancer Institute, 2008. http://planning.cancer.gov/ disease/Head-and-Neck-Snapshot.pdf
2. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004
3. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
4. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
5. Adelstein DJ, Lavertu P, Saxton JP, et al: Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88:876-883, 2000
6. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
7. Brockstein B, Haraf DJ, Rademaker AW, et al: Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol 15:1179-1186, 2004
8. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
9. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007
10. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003
11. Argiris A, Brockstein BE, Haraf DJ, et al: Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10:1956-1962, 2004
12. Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium: Clinical implications of multicentric origin. Cancer 6:963-968, 1953
13. Tsai HK, D'Amico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007
14. Tammemagi CM, Nerenz D, Neslund-Dudas C, et al: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294:1765-1772, 2005
15. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25:4952-4960, 2007
16. Pintilie M: Competing Risks: A Practical Perspective. Chichester, United Kingdom, John Wiley & Sons, 2006, pp 192-195
17. Latouche A, Porcher R: Sample size calculations in the presence of competing risks. Stat Med 26:5370-5380, 2007
18. Mell LK, Weichselbaum RR: More on cetuximab in head and neck cancer. N Engl J Med 357:2201-2202, 2007
19. Vokes EE, Stenson K, Rosen FR, et al: Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21:320-326, 2003
20. Haraf DJ, Rosen FR, Stenson K, et al: Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 9:5936-5943, 2003
21. Ahmed SM, Cohen EE, Haraf DJ, et al: Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC). J Clin Oncol 25:306s, 2007 (abstr 6028)
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Korn EL, Dorey FJ: Applications of crude incidence curves. Stat Med 11:813-829, 1992
24. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 8:400-409, 1993
25. Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
26. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
27. Prentice RL, Kalbfleisch J, Peterson A, et al: The analysis of failure times in the presence of competing risks. Biometrics 34:541-554, 1978
28. Lamont EB, Hayreh D, Pickett KE, et al: Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst 95:1370-1375, 2003
29. Freemantle N, Calvert M, Wood J, et al: Composite outcomes in randomized trials: Greater precision but with greater uncertainty? JAMA 289: 2554-2559, 2003
30. Arriagada R, Rutqvist LE, Kramar A, et al: Competing risks determining event-free survival in early breast cancer. Br J Cancer 66:951-957, 1992